Evidence map›Paper›PMID 24453974›Full record

ArticlePLoS pathogens2014

Gammaherpesviral gene expression and virion composition are broadly controlled by accelerated mRNA degradation.

Emma Abernathy, Karen Clyde, Rukhsana Yeasmin, Laurie T Krug, Al Burlingame, Laurent Coscoy, Britt Glaunsinger

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. The mProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Emma AbernathyDepartment of Plant and Microbial Biology, University of California at Berkeley, Berkeley, California, United States of America.
Karen ClydeDepartment of Plant and Microbial Biology, University of California at Berkeley, Berkeley, California, United States of America.
Rukhsana YeasminDepartment of Computer Science, Stony Brook University, Stony Brook, New York, United States of America.
Laurie T KrugDepartment of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, New York, United States of America.
Al BurlingameDepartment of Pharmaceutical Chemistry, University of California at San Francisco, San Francisco, United States of America.
Laurent CoscoyDepartment of Cell and Molecular Biology, University of California at Berkeley, Berkeley, California, United States of America.
Britt GlaunsingerDepartment of Plant and Microbial Biology, University of California at Berkeley, Berkeley, California, United States of America ; Department of Cell and Molecular Biology, University of California at Berkeley, Berkeley, California, United States of America.
University of California, Berkeley · USStony Brook University · USUniversity of California, San Francisco · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
Bio-Organic Biomedical Mass Spectromy ResourceP41GM103481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BURLINGAME, ALMA L · 2012 to 2015
$6.4M
Disruption of Cellular RNA Processing by Kaposi's Sarcoma-Associated HerpesvirusR01CA136367 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI Britt A Glaunsinger · 2010 to 2026
$5.8M
Escape from gammaherpesvirus-induced mRNA destructionR01CA160556 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI GLAUNSINGER, BRITT A · 2011 to 2015
$1.5M
NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA136367NCI NIH HHS R01 CA160556NCI NIH HHS R01 CA16056NIGMS NIH HHS 8P41GM103481NIGMS NIH HHS P41 GM103481
6 · The paper itself

Abstract

Lytic gammaherpesvirus infection restricts host gene expression by promoting widespread degradation of cytoplasmic mRNA through the activity of the viral endonuclease SOX. Though generally assumed to be selective for cellular transcripts, the extent to which SOX impacts viral mRNA stability has remained unknown. We addressed this issue using the model murine gammaherpesvirus MHV68 and, unexpectedly, found that all stages of viral gene expression are controlled through mRNA degradation. Using both comprehensive RNA expression profiling and half-life studies we reveal that the levels of the majority of viral mRNAs but not noncoding RNAs are tempered by MHV68 SOX (muSOX) activity. The targeting of viral mRNA by muSOX is functionally significant, as it impacts intracellular viral protein abundance and progeny virion composition. In the absence of muSOX-imposed gene expression control the viral particles display increased cell surface binding and entry as well as enhanced immediate early gene expression. These phenotypes culminate in a viral replication defect in multiple cell types as well as in vivo, highlighting the importance of maintaining the appropriate balance of viral RNA during gammaherpesviral infection. This is the first example of a virus that fails to broadly discriminate between cellular and viral transcripts during host shutoff and instead uses the targeting of viral messages to fine-tune overall gene expression.

Indexed as

RNA StabilityAnimalsChlorocebus aethiopsGene Expression Regulation, ViralHerpesviridae InfectionsMiceNIH 3T3 CellsRhadinovirusRNA, MessengerVero CellsVirionVirus ReplicationRNA, Messenger

Identifiers

PMID24453974
PMCPMC3894220
OpenAlexW2085990005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.